Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAR-T
Biotech
BMS' CAR-T cracks down on lupus, achieving sustained responses
One patient had a grade 3 case of immune effector cell-associated neurotoxicity syndrome, an adverse event associated with CAR-T therapy.
Nick Paul Taylor
Nov 14, 2024 10:00am
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Nov 14, 2024 5:59am
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Nov 8, 2024 4:47am
ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma
Nov 5, 2024 3:08pm
Cellectis drops one of its 3 clinical-stage CAR-Ts
Nov 5, 2024 7:15am
Sana strips back cancer, CNS programs while warning of layoffs
Nov 5, 2024 7:05am
